Myriad Genetics vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Myriad Genetics Inc (MYGN)

Q3 202622 Jun – 6 Aug 2026

▼2▲1

Myriad's Q2 Miss and Guidance Cut Crush Stock; Fraud Probe Adds Risk

Q2 revenue miss and guidance cut Myriad's Q2 revenue fell 11% to $190.7M, missing estimates, and the company slashed full-year revenue guidance by over 10% to $770–790M. This signals weakening demand and pricing, pushing the stock down sharply.
This is the core negative event that drove the stock down 46% and is new this period.
Securities fraud investigation Kirby McInerney LLP is investigating Myriad for potential securities fraud related to its Q2 results and guidance cut. This adds legal uncertainty and could lead to further financial penalties, weighing on the stock.
This is a new development that increases risk and could pressure the stock further.
Precise MRD test expansion Myriad expanded its Precise MRD test to breast, colorectal, and renal cancers, backed by positive study results. This opens a larger market and could drive future revenue growth, but the impact is longer-term.
This is a new positive development that could support future growth, though it was overshadowed by negative financials.

July 202622 Jun – 6 Aug 2026

▼2▲1

Myriad's Q2 Miss and Guidance Cut Crush Stock; Fraud Probe Adds Risk

Q2 revenue miss and guidance cut Myriad's Q2 revenue fell 11% to $190.7M, missing estimates, and the company slashed full-year revenue guidance by over 10% to $770–790M. This signals weakening demand and pricing, pushing the stock down sharply.
This is the core negative event that drove the stock down 46% and is new this period.
Securities fraud investigation Kirby McInerney LLP is investigating Myriad for potential securities fraud related to its Q2 results and guidance cut. This adds legal uncertainty and could lead to further financial penalties, weighing on the stock.
This is a new development that increases risk and could pressure the stock further.
Precise MRD test expansion Myriad expanded its Precise MRD test to breast, colorectal, and renal cancers, backed by positive study results. This opens a larger market and could drive future revenue growth, but the impact is longer-term.
This is a new positive development that could support future growth, though it was overshadowed by negative financials.

Latest22 Jun – 6 Aug 2026

▼2▲1

Myriad's Q2 Miss and Guidance Cut Crush Stock; Fraud Probe Adds Risk

Q2 revenue miss and guidance cut Myriad's Q2 revenue fell 11% to $190.7M, missing estimates, and the company slashed full-year revenue guidance by over 10% to $770–790M. This signals weakening demand and pricing, pushing the stock down sharply.
This is the core negative event that drove the stock down 46% and is new this period.
Securities fraud investigation Kirby McInerney LLP is investigating Myriad for potential securities fraud related to its Q2 results and guidance cut. This adds legal uncertainty and could lead to further financial penalties, weighing on the stock.
This is a new development that increases risk and could pressure the stock further.
Precise MRD test expansion Myriad expanded its Precise MRD test to breast, colorectal, and renal cancers, backed by positive study results. This opens a larger market and could drive future revenue growth, but the impact is longer-term.
This is a new positive development that could support future growth, though it was overshadowed by negative financials.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.